In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk (NYSE: NVO) ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the ...